Skip to content

ENAVATE SCIENCES GP, LLC

Follow

13F filer, CIK 1953107, New York, NY

ENAVATE SCIENCES GP, LLC reported $279,763,966 across 8 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.

Accepted , ingested 13F-HR 0001953107-26-000019

Period
2026-09-30
Reported value
$280M
Holdings
8
Top 10 weight
100%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BRVEnew+3,674,656$74.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ZBIOreduced-1,000,000-$27M
CAMPreduced-384,414-$1.55M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001953107-26-000019, largest first. % of portfolio is the value over $279,763,966, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,761,359 shares; 2025Q1: 3,761,359 shares; 2025Q2: 3,761,359 shares; 2025Q3: 3,761,359 shares; 2025Q4: 3,919,159 shares; 2026Q1: 3,919,159 shares; 2026Q2: 3,919,159 shares; 2026Q3: 2,919,159 shares 2,919,159$78.7M28.14%-1,000,000Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,478,261 shares; 2025Q1: 4,768,583 shares; 2025Q2: 4,768,583 shares; 2025Q3: 4,768,583 shares; 2025Q4: 4,768,583 shares; 2026Q1: 3,613,799 shares; 2026Q2: 3,613,799 shares; 2026Q3: 3,613,799 shares 3,613,799$77.7M27.79%0Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,674,656 shares 3,674,656$74.2M26.53%newTimeline
SIONSIONNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 2,478,030 shares; 2025Q2: 2,478,030 shares; 2025Q3: 2,478,030 shares; 2025Q4: 2,478,030 shares; 2026Q1: 2,478,030 shares; 2026Q2: 2,478,030 shares; 2026Q3: 2,478,030 shares 2,478,030$13M4.66%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,459,703 shares; 2025Q1: 2,459,703 shares; 2025Q2: 2,459,703 shares; 2025Q3: 2,459,703 shares; 2025Q4: 2,459,703 shares; 2026Q1: 2,459,703 shares; 2026Q2: 2,459,703 shares; 2026Q3: 2,459,703 shares 2,459,703$13M4.63%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,626,946 shares; 2025Q4: 2,626,946 shares; 2026Q1: 2,626,946 shares; 2026Q2: 2,626,946 shares; 2026Q3: 2,626,946 shares 2,626,946$10.8M3.85%0Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,788,150 shares; 2025Q1: 7,788,150 shares; 2025Q2: 7,788,150 shares; 2025Q3: 7,788,150 shares; 2025Q4: 7,788,150 shares; 2026Q1: 7,788,150 shares; 2026Q2: 7,788,150 shares; 2026Q3: 7,788,150 shares 7,788,150$8.1M2.9%0Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,785,802 shares; 2025Q1: 3,785,802 shares; 2025Q2: 3,785,802 shares; 2025Q3: 3,785,802 shares; 2025Q4: 3,035,825 shares; 2026Q1: 2,190,920 shares; 2026Q2: 1,425,541 shares; 2026Q3: 1,041,127 shares 1,041,127$4.21M1.5%-384,414Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001953107-26-000019 base2026-11-16